Eight analysts rate Simulations Plus stock Reduce
Published on 10/05/2026 at 21:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eight brokerages gave Simulations Plus stock an average Reduce rating and a USD 17.25 12-month target on September 25, 2026, according to MarketBeat. The breakdown was one sell rating and seven hold ratings, putting the target below the USD 18.46 opening price cited in that report.
Analyst target stays below the quote
The gap between the USD 17.25 average target and the USD 18.46 opening price was USD 1.21, or 6.55 percent below the opening price, on the comparison date used by MarketBeat. That cautious consensus contrasts with the company's latest reported quarter, where revenue exceeded expectations.
MarketBeat reported fiscal third-quarter 2026 revenue of USD 21.89 million versus USD 20.90 million expected. The USD 0.99 million difference equals 4.74 percent above consensus, giving investors a stronger operating figure than the rating label alone suggests.
FDA adoption adds a commercial signal
On September 17, 2026, the cosmetics regulatory science branch of the US Food and Drug Administration licensed ADMET Predictor for computational safety research, as Zonebourse reported. The agreement extends use of Simulations Plus technology beyond traditional pharmaceutical applications and links its modeling tools to regulatory research.
The company develops software and consulting services for drug discovery, development and regulatory decisions. Its portfolio includes GastroPlus, MonolixSuite, ADMET Predictor and DILIsym, while the investor-relations page describes ADMET Predictor as a machine-learning platform for absorption, distribution, metabolism, excretion and toxicity modeling.
Results date sets the next test
MarketBeat lists October 29, 2026 as the date for Simulations Plus fourth-quarter fiscal 2026 results and gives expected revenue of USD 17.44 million. That report will test whether the fiscal-year reporting pattern can support a valuation above the current consensus target.
Nasdaq quote remains below yearly high
On the Nasdaq listing, Simulations Plus was last at USD 18.50 on October 5, 2026 at 3:48 p.m. ET. The USD 374.1 million market capitalization and USD 11.09 to USD 21.01 52-week range put the quote 11.95 percent below the yearly high.
Simulations Plus stock facts
- Company: Simulations Plus, Inc.
- ISIN: US8292141053
- Ticker: SLP
- Primary exchange: NASDAQ
- Market capitalization: USD 374.1 million (as of October 5, 2026)
- 52-week range: USD 11.09-21.01 (as of October 5, 2026)
- Sector / Industry: Technology / Software - Application
- Next earnings date: October 29, 2026
